Drug intelligence / Profile preview

BOX202-6

Development stage: Preclinical
Lead developer: Bostal Pharma
Modality: Small Molecules
Administration: Intramuscular, Subcutaneous

Overview

BOX202-6 is a long-acting injectable (LAI) formulation being developed by Bostal Pharma for the treatment of schizophrenia. Designed as a 6-month (twice-yearly) depot injection, the therapy utilizes Bostal's proprietary drug delivery technologies to provide sustained and controlled release of its active pharmaceutical ingredient. By extending the dosing interval to six months, BOX202-6 aims to significantly improve treatment adherence and reduce relapse rates in patients with schizophrenia. The program is currently in the IND-enabling stage of development.

Other names: BOX202-6, 6M

Beyond the preview

Go deeper on BOX202-6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BOX202-6.

Explore the full profile